Currently, 66% of clinical trials are conducted in North America, Western Europe and Australia.
Currently, 66% of clinical trials are conducted in North America, Western Europe and Australia. The U.S. hosts 49% of clinical trial sites and generates approximately 40% of clinical data. Other regions have arisen in recent years. The main reasons behind this globalization trend are the availability of highly skilled professionals in new research markets, lower costs, faster patient recruitment that allows for earlier drug application approvals and concentrations of huge populations for future drug sales.
Central and Eastern Europe participates in about 13% of clinical trials conducted in Europe and in about 5% of those conducted globally.
However, this number was as high as 7.5% in 2006. In relative terms, the decline here goes as far as 28% over the last six years. It has been observed in all countries of this region, especially Poland, Croatia and the Baltic states.
In this Applied Clinical Trials article, Thomas Novak, Maxim Belotserkovsky, and Ginny Payeur look at whether this surprising finding represents a fluctuation or a new trend.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.